Leap Investments’s Amicus Therapeutics FOLD Stock Holding History

Leap Investments’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-140,400	Closed	-$1.13M	–	473
2019 Q3	$1.13M	Buy	+140,400	New	+$1.52M	0.56%	39

Other funds holding FOLD

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Leap Investments's FOLD Position: Q4 2019 in Review

Leap Investments sold out of Amicus Therapeutics (FOLD) in Q4 2019, closing a stake of 140,400 shares — an estimated $1.13M sold.

Leap Investments first reported a position in FOLD in Q3 2019 and held it in 1 quarter. The position peaked at $1.13M in Q3 2019. 224 funds tracked by Wall St. Rank hold FOLD as of Q4 2019.

Leap Investments reported no remaining Amicus Therapeutics position as of Q4 2019 after selling out during the quarter.
Leap Investments sold 140,400 Amicus Therapeutics shares in Q4 2019, an estimated $1.13M.
Leap Investments first reported a position in Amicus Therapeutics in Q3 2019 and held it in 1 quarter.
Leap Investments's Amicus Therapeutics position peaked at $1.13M in Q3 2019.
224 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.